Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our results suggest that CYP2D6 ultra-rapid metabolizer status contributes to venlafaxine-XR treatment remission in MDD patients; in particular, there is a PK-PD interaction with treatment remission associated with CYP2D6 URM phenotype and SLC6A4 5-HTTLPR L/L or SLC6A2 G1287A G/A genotype, respectively.
|
30578947 |
2019 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CYP-GUIDES (Cytochrome Psychotropic Genotyping Under Investigation for Decision Support) is a randomized controlled trial (RCT) comparing 2 outcomes in hospitalized patients with major depressive disorder (MDD) treated according to the patient's CYP2D6 genotype and functional status versus standard psychotropic therapy.
|
31838256 |
2019 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
BEFREE |
Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder.
|
29327975 |
2018 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
|
27187662 |
2016 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.
|
24528284 |
2014 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
47 patients with Major Depressive Disorder, treated with V 75 - 300 mg/day, underwent CYP2D6 genotyping using the INFINITI-CYP2D6 assay.
|
24660534 |
2014 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene.
|
23734807 |
2013 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
A total of 149 inpatients with a diagnosis of major depressive disorder at the Institute of Living, Hartford Hospital (CT, USA), were genotyped to detect altered alleles in the CYP2D6 gene.
|
23734807 |
2013 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder.
|
24014145 |
2013 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
|
23081704 |
2013 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
The impact of Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes on suicide attempt and suicide risk-a European multicentre study on treatment-resistant major depressive disorder.
|
23081704 |
2013 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study is to investigate the influence of the 5-HTTLPR (serotonin transporter-linked promoter region), cytochrome P450 2C19, and cytochrome P450 2D6 polymorphisms on escitalopram (ESC) and venlafaxine (VEN) responses in major depressive disorder.
|
24014145 |
2013 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications.
|
21861666 |
2011 |
Major Depressive Disorder
|
0.500 |
Biomarker
|
disease |
PSYGENET |
CYP2C9, CYP2C19 and CYP2D6 genotypes and clinical data were obtained for 150 consecutive, consenting hospital admissions with a diagnosis of major depressive disorder and who were treated with psychotropic medications.
|
21861666 |
2011 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The risk of major depression in CYP2D6*4/*4 was not significantly different from extensive metabolizers (OR = 0.85; 95% CI: 0.36-2.00; p = 0.72).
|
19374513 |
2009 |
Major Depressive Disorder
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This paper explores the link between CYP2D6 genotype and antidepressant-associated ADRs in outpatients being treated for major depression with either nortriptyline or fluoxetine.
|
14716707 |
2004 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen.
|
31800347 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.
|
31559573 |
2020 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Conclusion:</b><i>CYP2D6*10</i> pharmacogenetic-guided selective estrogen receptor modulator can be a cost-effective strategy in the Chinese patients with hormone receptor-positive breast cancer.
|
31769341 |
2020 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine.
|
31688392 |
2020 |
Mental Depression
|
0.400 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to determine the effectiveness of CYP2D6 pharmacogenetic screening to accelerate drug dosing in older patients with depression initiating nortriptyline or venlafaxine.
|
31688392 |
2020 |
Depressive disorder
|
0.400 |
Biomarker
|
disease |
BEFREE |
182 subjects diagnosed with depression and treated with these drugs were clinically and therapeutically characterized and submitted to the quantification of drug/metabolite plasma concentrations and genotyping of ABCB1, CYP2C9, CYP2C19, and CYP2D6 genes.
|
31120287 |
2020 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both poor and ultrarapid CYP2D6 metabolizers of tamoxifen have a worse prognosis for breast cancer compared with normal metabolizers after receiving a standard dose of tamoxifen.
|
31800347 |
2020 |
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
From the perspective of the Chinese healthcare system, CYP2D6*10 pharmacogenetic testing was cost effective for postmenopausal women with ER-positive early breast cancer.
|
31559573 |
2020 |